Whoop Adds Bloodwork Uploads Amid Spat With FDA Over How 'Medical' Its Wearable Is

  //health-fitness.news-articles.net/co .. over-how-medical-its-wearable-is.html
  Published in Health and Fitness on Thu, Oct 10nd, 2025 by PC Magazine

Whoop Expands Its Wellness Toolkit with Bloodwork Uploads Amid Ongoing FDA Debate

The wearable‑fitness company Whoop, known for its heart‑rate‑based strain and recovery metrics, has announced a new feature that lets users upload their lab‑test results directly into the Whoop ecosystem. The move comes as the firm wrestles with the U.S. Food & Drug Administration’s (FDA) ongoing scrutiny over whether its device qualifies as a “medical device” or can safely remain a consumer wellness gadget. According to a recent PCMag story, the partnership aims to give users a richer picture of their health by correlating wearable data with objective blood‑based biomarkers.

The Why Behind Bloodwork Integration

Whoop’s new “Bloodwork Upload” feature is part of a broader push to create a single, holistic view of an athlete’s or fitness enthusiast’s health. The company says users can now import results for common panels—lipid profiles, hemoglobin A1c, iron studies, and more—into the app’s Health Dashboard. By layering this objective data on top of its continuous physiological monitoring, Whoop hopes to empower users to spot trends that might otherwise go unnoticed.

“We’re always looking for ways to add more value for our members,” says Dan Glickman, Whoop’s Head of Product. “By letting people bring in their lab results, we’re giving them the context needed to interpret their sleep and recovery data in a more informed way.”

The feature, according to Whoop’s own documentation, will sync with several popular at‑home testing services, such as EverlyWell and 1‑Drop, that send results in a structured, machine‑readable format. The company claims all data remain encrypted on Whoop’s servers, with user‑controlled sharing options.

The FDA Ruckus

The FDA’s concerns aren’t new. Back in 2018, the agency issued guidance on the classification of “digital health” devices, clarifying that tools offering diagnostic or therapeutic advice are subject to regulatory oversight. Whoop’s flagship product, a wrist‑worn sensor that calculates “strain” and “recovery” scores, has consistently positioned itself as a wellness‑not‑medical device. This distinction matters because medical‑device approval involves rigorous pre‑market testing, clinical validation, and post‑market surveillance that are typically beyond the scope of a consumer‑fitness startup.

In July 2023, Whoop received a letter from the FDA that questioned whether the company’s software and data analytics could be considered medical advice, a trigger for potential regulation. The firm responded that it is “unambiguous” in its marketing that the product is not a medical device, and it has never been used for diagnosing or treating conditions. However, the FDA’s letter suggested that the new bloodwork upload capability might tip the scale—if a user’s lab results indicate abnormal values, the Whoop app could potentially influence health decisions.

The company’s latest move to enable users to upload their own bloodwork can be interpreted in two ways. First, it may be a proactive effort to demonstrate transparency and control over user data, thereby appeasing the FDA. Second, it might be a strategic step toward a “health‑tech” future where the line between consumer wellness and medical care continues to blur. In either case, Whoop is playing a risky game: if the FDA determines that the integration of lab data constitutes medical advice, Whoop may be forced to seek clearance as a medical device—an expensive and time‑consuming process.

Industry Context

Whoop is not alone in this tug‑of‑war. Other fitness‑tech companies—Fitbit, Garmin, Apple, and more—have all navigated the FDA’s regulatory maze in various ways. Apple’s HealthKit, for example, is a non‑medical framework that allows developers to read and write health data, but Apple itself is careful not to label its devices as medical instruments. Garmin has historically positioned its “Health Metrics” as wellness tools rather than diagnostic devices, while Fitbit’s “Health Snapshot” and “Activity” scores are similarly framed as general wellness metrics.

However, the regulatory landscape is shifting. The FDA has recently adopted a “Digital Health Innovation Action Plan” that intends to create a flexible framework for software‑as‑a‑device (SaMD). The agency is also launching a “Digital Health Innovation Action Plan” to facilitate the timely review of promising digital health solutions. This new environment may make it easier for companies like Whoop to obtain clearance for certain features—provided they can demonstrate safety, efficacy, and proper risk mitigation.

User and Market Reactions

Early responses from Whoop members are cautiously optimistic. “It’s great to see our bloodwork data in one place,” says longtime user Alex M. “But I worry about whether the app will flag something and push me to see a doctor. I don’t want to get hyped or panicked.” Meanwhile, health‑tech analysts note that this integration could give Whoop a competitive advantage by offering a more “comprehensive health dashboard” than its rivals.

Critics argue that adding bloodwork uploads may inadvertently give the impression that Whoop is a medical provider. “We’re in a space where data can be misinterpreted,” cautions Dr. Melissa T. of the Digital Health Institute. “Users might assume the app is telling them how to treat a condition when it’s really just a data aggregation platform.”

In response, Whoop has emphasized that the app will not provide medical diagnoses or treatment recommendations. “All our health insights are framed as general wellness trends,” Glickman says. “If a user notices a red flag, we recommend they consult a qualified health professional.”

What’s Next for Whoop and the FDA?

The FDA’s next move remains uncertain. The agency’s guidelines suggest that a product can be exempt if it meets a “consumer wellness” definition—no direct medical advice, no diagnostic claims, and no direct integration with health care systems. Whoop’s current marketing materials continue to stress this stance. But the company’s foray into bloodwork uploads could be seen as a blurring of lines.

Whoop’s leadership appears prepared to stay nimble. “We’re constantly testing the regulatory envelope,” Glickman said in a brief interview with PCMag. “If the FDA changes its position, we’re ready to adapt—whether that means a new compliance path or a pivot in product strategy.”

For consumers, the new feature offers a chance to see how their lab values might correlate with sleep, recovery, and overall strain metrics. Whether this leads to better health decisions—or unintended anxiety—remains to be seen.

For the wearable‑tech industry, Whoop’s decision highlights the growing tension between innovation and regulation. As more companies embed clinical data into consumer devices, the FDA’s regulatory approach will likely evolve to balance safety with the promise of personalized, data‑driven wellness. The next few months could see a decisive shift: either the FDA will grant a relaxed clearance pathway for such integrations, or it will take a stricter stance, pushing firms to seek full medical‑device approval. Whoever wins, the outcome will set a precedent for the future of digital health.